Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.

被引：0
|
作者：
Aapro, Matti S.
Demidchik, Yuri
Bondarenko, Igor
Siedakov, Igor
Sakaeva, Dina
Krishnamurthy, S.
Roman, Laslo
Lebedeva, Liudmila
Mefti, Fawzia
Ponomarova, Olga
Bachelot, Thomas Denis
Lytvyn, Lryna
Delaloge, Suzette
Kupp, Anita
Karchmit, Yauheniya
Bougnoux, Philippe
Campone, Mario
Martin, Miguel
机构：
[1] Clin Genolier, Genolier, Switzerland
[2] Belarusian Med Acad Postgrad Educ, Minsk, BELARUS
[3] Dnipropetrovsk City Multifield Clin Hosp 4, Dnepropetrovsk, Ukraine
[4] Reg Antitumor Ctr, Donetsk, Ukraine
[5] Republican Clin Oncol Dispensary, Ufa, Russia
[6] Kidway Mem Inst Oncol, Bangalore, Karnataka, India
[7] Leningrad Reg Oncol Dispensary, St Petersburg, Russia
[8] Clin Oncol Dispensary, Arkhangelsk, Russia
[9] Hop Rene Huguenin, Inst Curie, St Cloud, France
[10] City Oncol Hosp, Kiev, Ukraine
[11] Ctr Leon Berard, Dept Oncol Med, F-69373 Lyon, France
[12] Reg Oncol Hosp, Dnepropetrovsk, Ukraine
[13] Inst Cancerol Gustave Roussy, Villejuif, France
[14] North Estonia Med Ctr, Tallinn, Estonia
[15] Reg Clin Oncol Dispensary, Vitebsk, BELARUS
[16] CHU Bretonneau, Dept Med Oncol, F-37044 Tours, France
[17] Inst Cancerol Ouest, Nantes, France
[18] Hosp Univ Gregorio Maranon, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1013
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer
    Wist, EA
    Sommer, HH
    Ostenstad, B
    Risberg, T
    Bremnes, Y
    Mjaaland, I
    ACTA ONCOLOGICA, 2004, 43 (02) : 186 - 189
  • [42] Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial
    Xu, B.
    Sun, T.
    Zhang, Q.
    Zhang, P.
    Yuan, Z.
    Jiang, Z.
    Wang, X.
    Cui, S.
    Teng, Y.
    Hu, X-C
    Yang, J.
    Pan, H.
    Tong, Z.
    Li, H.
    Yao, Q.
    Wang, Y.
    Yin, Y.
    Sun, P.
    Zheng, H.
    Cheng, J.
    Lu, J.
    Zhang, B.
    Geng, C.
    Liu, J.
    Shen, K.
    Yu, S.
    Tang, L.
    Qiu, R.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 218 - 228
  • [43] Capecitabine and Oral Cyclophosphamide Combination in Taxane/Antrhracycline Resistant Metastatic Breast Cancer
    Ozet, Ahmet
    Uncu, Dogan
    Kuzhan, Okan
    Komurcu, Seref
    Ozturk, Mustafa
    Arpaci, Fikret
    Ozturk, Bekir
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (02): : 87 - 91
  • [44] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Barrios, Carlos H.
    Liu, Mei-Ching
    Lee, Soo Chin
    Vanlemmens, Laurence
    Ferrero, Jean-Marc
    Tabei, Toshio
    Pivot, Xavier
    Iwata, Hiroji
    Aogi, Kenjiro
    Lugo-Quintana, Roberto
    Harbeck, Nadia
    Brickman, Marla J.
    Zhang, Ke
    Kern, Kenneth A.
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) : 121 - 131
  • [45] Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy
    Mark Clemons
    Anil A. Joy
    Radhi Abdulnabi
    Mauricio Kotliar
    Jodi Lynch
    Johan P. Jordaan
    Neill Iscoe
    Karen Gelmon
    Breast Cancer Research and Treatment, 2010, 124 : 177 - 186
  • [46] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Carlos H. Barrios
    Mei-Ching Liu
    Soo Chin Lee
    Laurence Vanlemmens
    Jean-Marc Ferrero
    Toshio Tabei
    Xavier Pivot
    Hiroji Iwata
    Kenjiro Aogi
    Roberto Lugo-Quintana
    Nadia Harbeck
    Marla J. Brickman
    Ke Zhang
    Kenneth A. Kern
    Miguel Martin
    Breast Cancer Research and Treatment, 2010, 121 : 121 - 131
  • [47] Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy
    Clemons, Mark
    Joy, Anil A.
    Abdulnabi, Radhi
    Kotliar, Mauricio
    Lynch, Jodi
    Jordaan, Johan P.
    Iscoe, Neill
    Gelmon, Karen
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (01) : 177 - 186
  • [48] Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis
    Alsaloumi, Louai
    Shawagfeh, Shaima
    Abdi, Abdikarim
    Basgut, Bilgen
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12) : 694 - 702
  • [49] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [50] A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
    Li, Shufen
    Meng, Wenjing
    Zhang, Jibo
    Xie, Xiaojuan
    Hao, Chunfang
    Jia, Yongsheng
    Tong, Zhongsheng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 1069 - 1076
12345